Publications by authors named "Madeira Curry"
While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.
View Article and Find Full Text PDFArticle Synopsis
- This text is about a study on patients with aggressive B-cell lymphoma who didn't get better after their first treatment and received a second treatment called platinum-based immunochemotherapy.
- The study looked at how well this second treatment worked, focusing on how long patients lived without their disease getting worse (progression-free survival) and how long they lived overall (overall survival).
- The results showed that 44% of patients responded to the second treatment, but those who had problems early on after the first treatment did much worse compared to those who had problems later.